These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 25441439

  • 1. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials.
    Lambers Heerspink HJ, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K, Coresh J, Levey AS, Inker LA.
    Am J Kidney Dis; 2014 Dec; 64(6):860-6. PubMed ID: 25441439
    [Abstract] [Full Text] [Related]

  • 2. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials.
    Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, Coresh J, Greene T, Levey AS.
    Am J Kidney Dis; 2014 Dec; 64(6):848-59. PubMed ID: 25441438
    [Abstract] [Full Text] [Related]

  • 3. Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study.
    Greene T, Teng CC, Inker LA, Redd A, Ying J, Woodward M, Coresh J, Levey AS.
    Am J Kidney Dis; 2014 Dec; 64(6):867-79. PubMed ID: 25441440
    [Abstract] [Full Text] [Related]

  • 4. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.
    Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J.
    Am J Kidney Dis; 2014 Dec; 64(6):821-35. PubMed ID: 25441437
    [Abstract] [Full Text] [Related]

  • 5. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D.
    Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
    [Abstract] [Full Text] [Related]

  • 6. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.
    Badve SV, Palmer SC, Hawley CM, Pascoe EM, Strippoli GF, Johnson DW.
    Nephrol Dial Transplant; 2016 Sep; 31(9):1425-36. PubMed ID: 26163881
    [Abstract] [Full Text] [Related]

  • 7. Renal end points in clinical trials of kidney disease.
    Weldegiorgis M, de Zeeuw D, Heerspink HJ.
    Curr Opin Nephrol Hypertens; 2015 May; 24(3):284-9. PubMed ID: 25887898
    [Abstract] [Full Text] [Related]

  • 8. Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.
    Yang W, Xie D, Anderson AH, Joffe MM, Greene T, Teal V, Hsu CY, Fink JC, He J, Lash JP, Ojo A, Rahman M, Nessel L, Kusek JW, Feldman HI, CRIC Study Investigators.
    Am J Kidney Dis; 2014 Feb; 63(2):236-43. PubMed ID: 24182662
    [Abstract] [Full Text] [Related]

  • 9. Estimated GFR Trajectories of People Entering CKD Stage 4 and Subsequent Kidney Disease Outcomes and Mortality.
    Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z.
    Am J Kidney Dis; 2016 Aug; 68(2):219-228. PubMed ID: 26948835
    [Abstract] [Full Text] [Related]

  • 10. Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease.
    Perkins RM, Kirchner HL, Hartle JE, Bucaloiu ID.
    Clin Nephrol; 2013 Oct; 80(4):256-62. PubMed ID: 23993165
    [Abstract] [Full Text] [Related]

  • 11. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.
    Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis K.
    Am J Kidney Dis; 2020 Jan; 75(1):84-104. PubMed ID: 31473020
    [Abstract] [Full Text] [Related]

  • 12. Clinical risk implications of the CKD Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) Study equation for estimated GFR.
    Matsushita K, Tonelli M, Lloyd A, Levey AS, Coresh J, Hemmelgarn BR, Alberta Kidney Disease Network.
    Am J Kidney Dis; 2012 Aug; 60(2):241-9. PubMed ID: 22560843
    [Abstract] [Full Text] [Related]

  • 13. Short-term change in kidney function and risk of end-stage renal disease.
    Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, Matsushita K, Hemmelgarn BR.
    Nephrol Dial Transplant; 2012 Oct; 27(10):3835-43. PubMed ID: 22764191
    [Abstract] [Full Text] [Related]

  • 14. GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.
    Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, Simon AL, Ying J, Beck GJ, Wanner C, Floege J, Li PK, Perkovic V, Vonesh EF, Greene T.
    J Am Soc Nephrol; 2019 Sep; 30(9):1735-1745. PubMed ID: 31292197
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
    Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R.
    Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
    [Abstract] [Full Text] [Related]

  • 16. Sex Differences in the Progression of CKD Among Older Patients: Pooled Analysis of 4 Cohort Studies.
    Minutolo R, Gabbai FB, Chiodini P, Provenzano M, Borrelli S, Garofalo C, Bellizzi V, Russo D, Conte G, De Nicola L, Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology.
    Am J Kidney Dis; 2020 Jan; 75(1):30-38. PubMed ID: 31409508
    [Abstract] [Full Text] [Related]

  • 17. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.
    Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS.
    JAMA; 2014 Jun 25; 311(24):2518-2531. PubMed ID: 24892770
    [Abstract] [Full Text] [Related]

  • 18. Change in novel filtration markers and risk of ESRD.
    Rebholz CM, Grams ME, Matsushita K, Selvin E, Coresh J.
    Am J Kidney Dis; 2015 Jul 25; 66(1):47-54. PubMed ID: 25542414
    [Abstract] [Full Text] [Related]

  • 19. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe.
    Ryom L, Kirk O, Lundgren JD, Reiss P, Pedersen C, De Wit S, Buzunova S, Gasiorowski J, Gatell JM, Mocroft A, EuroSIDA in EuroCoord.
    HIV Med; 2013 Sep 25; 14(8):503-8. PubMed ID: 23590641
    [Abstract] [Full Text] [Related]

  • 20. Change in estimated glomerular filtration rate and outcomes in chronic kidney disease.
    Ferguson TW, Komenda P, Tangri N.
    Curr Opin Nephrol Hypertens; 2016 May 25; 25(3):240-4. PubMed ID: 26950591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.